

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	John Walter Liebeschuetz	Group Art Unit: 1624
Serial No.:	10/803,157	
Application Date:	18 March 2004	Conf No.: 6498
For:	Serine Protease Inhibitors	
Docket No.:	X14659B	Examiner: K. Habte

TERMINAL DISCLAIMER UNDER 37 CFR 1.321(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

Identification of Person Making This Disclaimer

I, Thomas E. Jackson, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

Extent of Interest and Record of Assignment in PTO

ELI LILLY AND COMPANY, an Indiana Corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above (a divisional of Serial No. 10/030,187) by virtue of:

A. An assignment from certain inventors, of the patent application identified above, which was recorded in the Patent and Trademark Office at Reel 012780, Frame 0710, at Reel 012780, Frame 0671, at Reel 012780, Frame 0652, at Reel 012780, Frame 0759, at Reel 012780, Frame 0684, at Reel 012780, Frame 0737, and at Reel 012780, Frame 0916.

AND

B. A chain of title from the remaining inventors, of the patent application identified above, to the current assignee as shown below:

1. An assignment from the remaining inventors, of the patent application identified above, to PROTHERICS MOLECULAR DESIGN LIMITED, which was recorded in the Patent and Trademark Office at Reel 012780, Frame 0126.
2. An assignment from PROTHERICS MOLECULAR DESIGN LIMITED to ELI LILLY AND COMPANY, which was recorded in the Patent and Trademark Office at Reel 012780, Frame 0677.

Disclaimer

The owner hereby disclaims the terminal part of any patent granted on this application, which would extend beyond the expiration date of United States Patent No. 6,936,611 and hereby agrees that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,936,611.

The owner does not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,936,611 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

Fee Payment

The Electronic Patent Application Fee Transmittal form accompanying this response provides authorization to charge any requisite fee (other than the Issue Fee and Publication Fee) to Deposit Account No. 05-0840.

Respectfully submitted,

/Thomas E. Jackson/

Thomas E. Jackson
Patent Attorney
Registration No. 33064
Phone: 317/277-3735

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

23 April 2007